FDA Approves Novartis' Pluvicto for Prostate Cancer Patients
March 28, 2025 — Novartis has announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu ...
Novartis Announces Temporary Halt in Production of Lutathera and ...
May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...